Resources

How to unlock the UK's innovative life sciences and biotech potential

Jane Wall discusses investment in Alchemab Therapeutics, Life Sciences Sector Plan: one year on, regulatory and trade links, Women in Biotech and BIA members lounge

Poolbeg Pharma today announces that the first patient has been dosed in the POLB 001 TOPICAL clinical trial.

How we boost entry-level diversity up to the senior level

Applications are now open for BIA's 2027 Charity Partnership

Autolomous and Cellular Origins today announce end-to-end integration of their respective platforms, bringing full automation and digitisation to the entire cell therapy manufacturing process.

Lucideon is expanding its global support for medical device innovation with the launch of a new biocompatibility laboratory in Greenville, South Carolina. Working alongside its UK cell biology laboratory, the new facility will provide a comprehensive range of biocompatibility testing and materials characterisation services from a single source, helping manufacturers accelerate product development, meet regulatory requirements, and bring safer medical devices to market with greater confidence. The investment strengthens Lucideon’s ability to support the next generation of medical technologies, from advanced implants and biomaterials to wearable devices, while helping protect patient safety worldwide. Read the full story to discover how Lucideon is creating a global biocompatibility and materials performance solution for medical device innovators.

Discover how BIA members influenced the UK Life Sciences Sector Jobs Plan, addressing critical biotech talent shortages, lab skills and AI innovation

Boyds, a leading global drug development consultancy, is pleased to announce the appointment of Laurence Skillern as Chief Medical Officer.

EnteroBiotix announced that the first patient has been dosed in RISE, its Phase 2b clinical trial evaluating EBX-102-02 in moderate-to-severe irritable bowel syndrome with constipation (IBS-C).

Coulter Partners successfully led a search for Salvia BioElectronics B.V. to place Jill Schiaparelli as Chair of its Board of Directors.

Each month, our Policy and Public Affairs team will showcase how we are championing members’ voices in Government and Parliament.

Chris Molloy on scale-up policy, improving treatments pipeline, LSSP, GMM regulation, LLSW, MDUK's Pedal Paddle Peak and Dr Sally Ann Forsyth OBE

Key takeaways as another BIA Summer Party 2026 delivers for the life sciences sector

The Global Talent visa route has been made easier for research-intensive businesses to attract international researchers and specialists

Myricx Bio reached agreement to be acquired by Novartis for up to $1.5 billion.

Astex has entered into an exclusive, worldwide research collaboration and license agreement with Genentech.

Brandon Capital announced the successful exit of its portfolio company Myricx Bio.

Craig Marshall, $1.5B OrganOx exit CEO, joins Oxford Medical Products board